Lumexa Imaging Holdings, Inc. Common Stock
Lumexa Imaging Holdings, Inc. manages and operates diagnostic imaging centers throughout the United States. These facilities deliver a comprehensive range of outpatient medical imaging solutions, encompassing advanced procedures like Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Positron Emission…
1D
+0.0%
1W
+2.3%
1M
-7.5%
6M
+11.6%
YTD
-41.7%
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~130% stronger price swings than usual
PRICE TARGET LOW
US$13.00
CONSENSUS
US$16.40
MEDIAN
US$17.00
PRICE TARGET HIGH
US$18.00
1
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Strong Buy
As of: 28/08/2026
P/E
-28.69
P/B
1.68
EV/EBITDA
16.95
RETURN ON EQUITY
0.4%
NET MARGIN
1.0%
DEBT/EQUITY
1.59
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
99.6%
FLOAT SHARES
95,670,114
AVG. DAILY VOLUME (30D)
392,766
BRODNAX BRETT
Cooper Henry Lee
EISENBERG GLENN A
Joseph Molly
Karlin Bridget E
Lumexa Imaging Holdings, Inc. Common Stock is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Caitlin Zulla, the company employs around 5,000 people.
The IPO was on 11/12/2025; the stock trades on NASDAQ under the ticker LMRI.
2 analysts rate the stock, the consensus is Strong Buy (as of 28/08/2026).
The average price target is US$16.40, ranging from US$13.00 to US$18.00, with a median of US$17.00.
This is an external assessment, not a statement by Market Jury.
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 130% stronger than usual.
No, Lumexa Imaging Holdings currently does not pay a dividend.
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
Clicking "Analyze stock" lets five strategies assess Lumexa Imaging Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.